{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:40:40Z","timestamp":1792518040699,"version":"4.5.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck & Co Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme United Kingdom","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.vaccine.2026.128516","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T08:51:58Z","timestamp":1774515118000},"page":"128516","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["A significant decrease in anogenital warts incidence following the implementation of a national human papillomavirus immunization program in Israel"],"prefix":"10.1016","volume":"80","author":[{"given":"Ilona","family":"Shapiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bekana K.","family":"Tadese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moshe","family":"Hoshen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Ting","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha","family":"Chohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tal","family":"Patalon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei (Vivian)","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sivan","family":"Gazit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.vaccine.2026.128516_bb0005","doi-asserted-by":"crossref","DOI":"10.1097\/OLQ.0000000000000193","article-title":"The estimated lifetime probability of acquiring human papillomavirus in the United States","volume":"41","author":"Chesson","year":"2014","journal-title":"Sex Transm Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128516_bb0010","first-page":"122","article-title":"Human papillomavirus: the usefulness of risk factors in determining who should get vaccinated","volume":"1","author":"Dempsey","year":"2008","journal-title":"Rev Obstet Gynecol"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128516_bb0015","first-page":"328","article-title":"Clinical use of the Onclarity test with extended HPV genotyping and phenotyping in patients with suspected squamous intraepithelial lesions","volume":"95","author":"Pruski","year":"2024","journal-title":"Ginekol Pol"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128516_bb0020","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv086","article-title":"US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines","volume":"107","author":"Saraiya","year":"2015","journal-title":"JNCI: Journal of the National Cancer Institute"},{"issue":"7","key":"10.1016\/j.vaccine.2026.128516_bb0025","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1002\/ijc.24116","article-title":"Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis","volume":"124","author":"De Vuyst","year":"2009","journal-title":"Int J Cancer"},{"issue":"9895","key":"10.1016\/j.vaccine.2026.128516_bb0030","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S0140-6736(13)60022-7","article-title":"Human papillomavirus and cervical cancer","volume":"382","author":"Crosbie","year":"2013","journal-title":"The Lancet"},{"issue":"8","key":"10.1016\/j.vaccine.2026.128516_bb0035","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1111\/jdv.16522","article-title":"2019 IUSTI-Europe guideline for the management of anogenital warts","volume":"34","author":"Gilson","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10","key":"10.1016\/j.vaccine.2026.128516_bb0040","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1185\/03007990903136378","article-title":"Assessing incidence and economic burden of genital warts with data from a US commercially insured population","volume":"25","author":"Hoy","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.vaccine.2026.128516_bb0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2334-13-39","article-title":"Systematic review of the incidence and prevalence of genital warts","volume":"13","author":"Patel","year":"2013","journal-title":"BMC Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128516_bb0050","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/j.1743-6109.2008.01151.x","article-title":"HPV infection in women: psychosexual impact of genital warts and intraepithelial lesions","volume":"6","author":"Graziottin","year":"2009","journal-title":"J Sex Med"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128516_bb0055","first-page":"1","article-title":"Natural history of genital warts","volume":"47","author":"Oriel","year":"1971","journal-title":"Br J Vener Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128516_bb0060","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1086\/597071","article-title":"Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a Quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine","volume":"199","author":"Garland","year":"2009","journal-title":"J Infect Dis"},{"issue":"5a","key":"10.1016\/j.vaccine.2026.128516_bb0065","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/S0002-9343(97)00179-4","article-title":"Clinical presentation and natural course of anogenital warts","volume":"102","author":"Handsfield","year":"1997","journal-title":"Am J Med"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128516_bb0070","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.clindermatol.2013.08.014","article-title":"Genital warts and other HPV infections: established and novel therapies","volume":"32","author":"Fathi","year":"2014","journal-title":"Clin Dermatol"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128516_bb0075","first-page":"25","article-title":"Genital warts: a comprehensive review","volume":"5","author":"Yanofsky","year":"2012","journal-title":"J Clin Aesthet Dermatol"},{"key":"10.1016\/j.vaccine.2026.128516_bb0080","author":"World Health Organization, Human papillomavirus (HPV) vaccination coverage"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128516_bb0085","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/cid\/ciw354","article-title":"Impact and effectiveness of the quadrivalent human papillomavirus vaccine: a systematic review of 10 years of real-world experience","volume":"63","author":"Garland","year":"2016","journal-title":"Rev Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128516_bb0090","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/infdis\/jit192","article-title":"Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and nutrition examination surveys, 2003\u20132010","volume":"208","author":"Markowitz","year":"2013","journal-title":"J Infect Dis"},{"issue":"10","key":"10.1016\/j.vaccine.2026.128516_bb0095","doi-asserted-by":"crossref","DOI":"10.3390\/v17101377","article-title":"Impact of vaccinating adult women who are HPV-positive or with confirmed cervical SIL with the 9-valent vaccine\u2014a systematic review","volume":"17","author":"Pruski","year":"2025","journal-title":"Viruses"},{"issue":"37","key":"10.1016\/j.vaccine.2026.128516_bb0100","doi-asserted-by":"crossref","first-page":"5469","DOI":"10.1016\/j.vaccine.2023.07.031","article-title":"Quadrivalent HPV vaccine effectiveness against anogenital warts: a registry-based study of 2,2 million individuals","volume":"41","author":"Nyg\u00e5rd","year":"2023","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2026.128516_bb0105","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/jnci\/djt032","article-title":"Quadrivalent human papillomavirus vaccine effectiveness: a Swedish national cohort study","volume":"105","author":"Leval","year":"2013","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"10.1016\/j.vaccine.2026.128516_bb0110","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1136\/sextrans-2011-050234","article-title":"The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme","volume":"87","author":"Read","year":"2011","journal-title":"Sex Transm Infect"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128516_bb0115","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/OLQ.0b013e31827bd66b","article-title":"Significant decrease in the incidence of genital warts in young Danish women after implementation of a national human papillomavirus vaccination program","volume":"40","author":"Baandrup","year":"2013","journal-title":"Sex Transm Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128516_bb0120","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1136\/sextrans-2014-051813","article-title":"Ongoing decline in genital warts among young heterosexuals 7 years after the Australian human papillomavirus (HPV) vaccination programme","volume":"91","author":"Chow","year":"2014","journal-title":"Sex Transm Infect"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128516_bb0125","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.ygyno.2017.06.001","article-title":"Impact of quadrivalent human papillomavirus vaccine on genital warts in an opportunistic vaccination structure","volume":"146","author":"Lurie","year":"2017","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128516_bb0130","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/EDE.0b013e3181d61eeb","article-title":"Negative controls: a tool for detecting confounding and bias in observational studies","volume":"21","author":"Lipsitch","year":"2010","journal-title":"Epidemiology"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128516_bb0135","doi-asserted-by":"crossref","DOI":"10.1097\/OLQ.0000000000001103","article-title":"Temporal trends in the incidence of Anogenital warts: impact of human papillomavirus vaccination","volume":"47","author":"Naleway","year":"2020","journal-title":"Sex Transm Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128516_bb0140","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1093\/infdis\/jis405","article-title":"Incidence of genital warts in Sweden before and after quadrivalent human papillomavirus vaccine availability","volume":"206","author":"Leval","year":"2012","journal-title":"J Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128516_bb0145","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1007\/s00404-024-07692-y","article-title":"The impact of Germany's human papillomavirus immunization program on HPV-related anogenital diseases: a retrospective analysis of claims data from statutory health insurances","volume":"310","author":"Goodman","year":"2024","journal-title":"Arch Gynecol Obstet"},{"issue":"7","key":"10.1016\/j.vaccine.2026.128516_bb0150","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/sti.2009.037788","article-title":"Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women","volume":"85","author":"Fairley","year":"2009","journal-title":"Sex Transm Infect"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128516_bb0155","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/OLQ.0000000000000418","article-title":"Significant reduction in the incidence of genital warts in young men 5 years into the Danish human papillomavirus vaccination program for girls and women","volume":"43","author":"Bollerup","year":"2016","journal-title":"Sex Transm Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128516_bb0160","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0267646","article-title":"Incidence of anogenital warts after the introduction of the quadrivalent HPV vaccine program in Manitoba, Canada","volume":"17","author":"Righolt","year":"2022","journal-title":"PloS One"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128516_bb0165","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/cid\/ciw354","article-title":"Impact and effectiveness of the Quadrivalent human papillomavirus vaccine: a systematic review of 10 years of real-world experience","volume":"63","author":"Garland","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128516_bb0170","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1017\/S0950268817002813","article-title":"Annual prevalence and economic burden of genital warts in Korea: health insurance review and assessment (HIRA) service data from 2007 to 2015","volume":"146","author":"Park","year":"2018","journal-title":"Epidemiol Infect"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128516_bb0175","doi-asserted-by":"crossref","first-page":"e1131","DOI":"10.1542\/peds.2014-2961","article-title":"The early benefits of human papillomavirus vaccination on cervical dysplasia and anogenital warts","volume":"135","author":"Smith","year":"2015","journal-title":"Pediatrics"},{"issue":"15","key":"10.1016\/j.vaccine.2026.128516_bb0180","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1016\/j.vaccine.2018.02.097","article-title":"Substantially reduced incidence of genital warts in women and men six years after HPV vaccine availability in Sweden","volume":"36","author":"Herweijer","year":"2018","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128516_bb0185","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1071\/SH19061","article-title":"Epidemiology of gonorrhoea: a global perspective","volume":"16","author":"Kirkcaldy","year":"2019","journal-title":"Sex Health"},{"key":"10.1016\/j.vaccine.2026.128516_bb0190","series-title":"Gonorrhoea In: ECDC. Annual Epidemiological Report for 2022","author":"European Centre for Disease Prevention and Control","year":"2024"},{"key":"10.1016\/j.vaccine.2026.128516_bb0195","series-title":"Chlamydia In: ECDC. Annual Epidemiological Report for 2022, in Annual Epidemiological Report for 2022","author":"European Centre for Disease Prevention and Control","year":"2024"},{"issue":"8","key":"10.1016\/j.vaccine.2026.128516_bb0200","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1080\/20477724.2023.2239052","article-title":"HPV and Covid-19 era: effects of nonpharmaceutical interventions on HPV transmission","volume":"117","author":"Luigi","year":"2023","journal-title":"Pathog Glob Health"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128516_bb0205","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1097\/OLQ.0000000000001306","article-title":"Impact of the COVID-19 pandemic on sexually transmitted infection clinic visits","volume":"48","author":"Tao","year":"2021","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.vaccine.2026.128516_bb0210","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1136\/sextrans-2020-054805","article-title":"Reporting of sexually transmitted infections during the COVID-19 pandemic","volume":"97","author":"Crane","year":"2021","journal-title":"Sex Transm Infect"},{"key":"10.1016\/j.vaccine.2026.128516_bb0215","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1136\/sextrans-2022-055656","article-title":"Effect of COVID-19 pandemic restrictions on chlamydia and gonorrhoea notifications and testing in Queensland, Australia: an interrupted time series analysis","volume":"99","author":"Dalmau","year":"2023","journal-title":"Sex Transm Infect"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128516_bb0220","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1080\/03630242.2023.2223721","article-title":"Correlations of HPV vaccine uptake among eight-grade students in Israel: the importance of ethnicity and level of religious observance","volume":"63","author":"Wortsman","year":"2023","journal-title":"Women Health"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128516_bb0225","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1186\/s12939-021-01523-1","article-title":"Factors associated with seasonal influenza and HPV vaccination uptake among different ethnic groups in Arab and Jewish society in Israel","volume":"20","author":"Shahbari","year":"2021","journal-title":"Int J Equity Health"},{"key":"10.1016\/j.vaccine.2026.128516_bb0230","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines12121385","article-title":"HPV vaccines among university students: understanding barriers and facilitators of vaccine uptake","volume":"12","author":"Malik","year":"2024","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2026.128516_bb0235","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2458-10-378","article-title":"Knowledge of human papillomavirus infection and its prevention among adolescents and parents in the greater Milan area, Northern Italy","volume":"10","author":"Pelucchi","year":"2010","journal-title":"BMC Public Health"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128516_bb0240","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s12879-016-1347-z","article-title":"Trends in genital warts by socioeconomic status after the introduction of the national HPV vaccination program in Australia: analysis of national hospital data","volume":"16","author":"Smith","year":"2016","journal-title":"BMC Infect Dis"},{"issue":"15","key":"10.1016\/j.vaccine.2026.128516_bb0245","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1017\/S0950268816001679","article-title":"Examining the role of socioeconomic deprivation in ethnic differences in sexually transmitted infection diagnosis rates in England: evidence from surveillance data","volume":"144","author":"Furegato","year":"2016","journal-title":"Epidemiol Infect"}],"updated-by":[{"DOI":"10.1016\/j.vaccine.2026.128695","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T00:00:00Z","timestamp":1783728000000}}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26003245?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26003245?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:01:51Z","timestamp":1792515711000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26003245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":49,"alternative-id":["S0264410X26003245"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128516","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A significant decrease in anogenital warts incidence following the implementation of a national human papillomavirus immunization program in Israel","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128516","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s) and Merck & Co., Inc., Rahway, NJ, USA and its affiliates. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"128516"}}